Aethlon Medical

Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. It develops Aethlon Hemopurifier, which is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The firm operates through the following segments: Aethlon and ESI. The Aethlon segment is involved in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce in 1991 and is headquartered in San Diego, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Aethlon Medical Advances Hemopurifier, Eyes Clinical Trials

Aethlon Medical is poised for pivotal clinical trials in Australia, focusing on its Hemopurifier technology's application in cancer treatment. Financially, the company has maintained a stable cash flow, managing a modest increase in expenses. The upcoming trials and potential expansion into the organ transplant sector highlight promising growth areas.

Aethlon Medical reports financial progress and global trial expansions

Aethlon Medical's Q1 2025 earnings call highlighted financial improvements, progress in Hemopurifier research, and global clinical trial expansions.
While challenges like expense projections and trial paperwork exist, opportunities in therapy enhancement and market expansion are promising for Aethlon.
The company's commitment to innovation, financial efficiency, and stakeholder communication bodes well for its future growth and success.
Investors can find confidence in Aethlon's strategic focus on advancing therapies and expanding its global reach in the oncology space.

Aethlon Medical reports strong Q2 performance amidst oncology trial progress

Aethlon Medical's Q2 2025 performance showcased financial stability, progress in oncology trials, and strategic cost reductions.
While challenges like trial complexities and data management exist, the company's strengths in innovation and transparency offer growth opportunities.
Navigating operational challenges and leveraging trial successes can drive Aethlon's long-term success in the healthcare industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aethlon Medical, Inc. (AEMD) CEO Tim Rodell on Q2 2020 Results - Earnings Call Transcript

Aethlon Medical, Inc. (AEMD) CEO Tim Rodell on Q1 2020 Results - Earnings Call Transcript

Aethlon Medical, Inc. (AEMD) CEO Dr.

News for Aethlon Medical Stock (AEMD)